Research programme: penetratin conjugates - Cyclacel Pharmaceuticals

Drug Profile

Research programme: penetratin conjugates - Cyclacel Pharmaceuticals

Alternative Names: CYC 300

Latest Information Update: 16 Feb 2010

Price : $50

At a glance

  • Originator Cyclacel Pharmaceuticals
  • Class Peptides
  • Mechanism of Action DNA topoisomerase I inhibitors; Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 28 Mar 2006 Xcyte Therapies has merged with Cyclacel to form Cyclacel Pharmaceuticals
  • 03 Mar 2006 This programme is still in active development
  • 02 Mar 2004 Compounds from the CYC300 research programme are available for licensing worldwide (
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top